Our team was participating in the 43rd Annual Meeting of the German Pancreas Club from February 15th – 17th, 2024. Our team members have been actively engaged in the Deutscher Pankreasclub lectures, poster sessions, and workshops, focusing on basic science breakthroughs in pancreatic cancer, along with the latest clinical and basic science innovations. The program […]
New study from Frankfurt University Hospital, Prof. Vogl has been published “Degradable Starch Microspheres Transarterial Chemoembolization with or without Lipiodol for Liver Metastases from Pancreatic Cancer: A Prospective Randomized Trial”. Check out the link below for the full article. Read More
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today 2023-09-08 16:05, announces the establishment of a collaboration and exclusive worldwide distribution agreement with the global medical device company Sirtex Medial pertaining to its chemoembolization product EmboCept® S DSM 50 µm. The main purpose is to accelerate internationalization, drive growth in new geographic areas, and […]
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today 2023-06-28 11:05 announces that the company has established a collaboration with Charité – Universitätsmedizin Berlin to evaluate the combination of its vascular embolic agent EmboCept® S DSM 50 µm and immunotherapy. As a first step of the collaboration, the parties are planning a study to […]
Magle Group (Nasdaq Stockholm First North Growth Market: MAGLE) today 2023-04-27 08:30 announces the presentation of data from the company’s first post-market clinical follow-up study of SmartPAN® – an innovative first-in-class medical device developed to improve the outcome of pancreatic surgery. The results were presented at the 140th German Surgery Congress, April 26-28th in Munich. […]